---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-001843"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:20:07.841992+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BridgeBio issues $632.5M of 0.75% convertible notes due 2033, prefunds repayment of 2027 notes

## Summary
- Aggregate $632.5M principal (incl. $82.5M initial purchasers' option), 0.75% coupon, due Feb 1, 2033.
- Net proceeds ~$619.3M; intended to repurchase, settle, or repay at maturity the 2.50% 2027 notes.
- Concurrent $82.5M share repurchase: 1,081,825 shares at $76.26/share from note purchasers.
- Initial conversion price ~$110.58/share, a ~45% premium over Jan 15 close of $76.26.
- Notes are senior unsecured; redemption permitted after Feb 6, 2030 if stock >=130% of conversion price.

## SEC filing metadata
- accession: 0001140361-26-001843
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126001843/0001140361-26-001843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126001843/ef20063486_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-001843
- JSON: https://secwatch.observer/filing/0001140361-26-001843.json
- Plain text: https://secwatch.observer/filing/0001140361-26-001843.txt

## Key facts
- Debt Financings
  BridgeBio Pharma, Inc. incurred convertible notes of $632.5 million aggregate principal amount with qualified institutional buyers at 0.75% per year maturing February 1, 2033.
  - Instrument: convertible notes
  - Principal: $632.5 million aggregate principal amount
  - Counterparty: qualified institutional buyers
  - Rate: 0.75% per year
  - Maturity: February 1, 2033
  - Event: incurrence
  source text: BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036126001843/0001140361-26-001843-index.htm
- Material Agreements
  BridgeBio Pharma, Inc. entered into 0.75% Convertible Senior Notes due 2033 Indenture with U.S. Bank Trust Company, National Association valued at $632,500,000 aggregate principal amount (effective 2026-01-21).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: U.S. Bank Trust Company, National Association
  - Value: $632,500,000 aggregate principal amount
  - Effective: 2026-01-21
  source text: On January 21, 2026, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036126001843/0001140361-26-001843-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.